Millennium Management Reduces Stake in Contineum Therapeutics (CTNM) Below 5% Threshold

Millennium Management LLC, along with Millennium Group Management LLC and Israel A. Englander, filed a Schedule 13G/A on July 17, 2026, regarding their holdings in Contineum Therapeutics, Inc. (CTNM). The filing indicates a significant reduction in their position. As of the event date on June 30, 2026, the reporting persons beneficially owned 931,709 shares of Class A Common Stock, representing 2.8% of the class. This is a decrease from their previous reported ownership of 1,658,349 shares, which constituted a 5.1% stake in the company. Because their ownership has fallen below the 5% threshold, this amendment serves to report that they are no longer beneficial owners of more than five percent of the issuer's securities. The shares are held by entities subject to the voting control and investment discretion of Millennium Management LLC, managed by Millennium Group Management LLC and ultimately overseen by Israel A. Englander. The filing was made under Rule 13d-1(c) and includes a joint filing agreement between the parties.